telisotuzumab

Telisotuzumab (formerly ABT-700) is a humanized monoclonal antibody that acts as an antagonist against the c-Met receptor (hepatocyte growth factor receptor). Originally developed by Pierre Fabre as h224G11 and subsequently licensed by AbbVie (formerly Abbott), it is designed to treat advanced solid tumors characterized by MET amplification or c-Met overexpression. By binding to c-Met, telisotuzumab inhibits the activation of the receptor by its ligand, hepatocyte growth factor (HGF), thereby suppressing downstream signaling pathways involved in tumor cell proliferation, survival, and metastasis. Clinical evaluation has focused on its safety and efficacy in patients with MET-amplified solid tumors, including gastric, esophageal, and ovarian cancers. It should be distinguished from telisotuzumab vedotin (ABBV-399), which is an antibody-drug conjugate utilizing the same antibody backbone.

Other names

telisotuzumab